Table 2.
Eradication rates of each therapy group.
| Variables | TBQT | TAD | BQT | TBQT vs. BQT | TAD vs. BQT | ||
|---|---|---|---|---|---|---|---|
| P for difference | P for noninferority | P for difference | P for noninferority | ||||
| ITT | 86.3 (138/160) | 85.5 (136/159) | 77.2 (115/149) | 0.039 | <0.001 | 0.059 | <0.001 |
| 95% CI | 80.9–91.6% | 80.8–90.1% | 70.5–83.9% | ||||
| PP | 87.3 (138/158) | 87.2 (136/156) | 77.7 (115/148) | 0.026 | <0.001 | 0.029 | <0.001 |
| 95% CI | 82.4–92.1% | 82.3–92.0% | 70.8–84.6% | ||||
ITT, intention-to-treat; PP, per protocol; CI, confidence interval; BQT, rabeprazole 10 mg twice daily, compound bismuth aluminate granules 2.6 g thrice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily; TAD, tegoprazan 50 mg twice daily, amoxicillin 1 g thrice daily; TBQT, tegoprazan 50 mg twice daily, compound bismuth aluminate granules 2.6 g thrice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily.